Spots Global Cancer Trial Database for The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Official Title: PD-1 Inhibitor Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer (STARS-GC01): A Single-arm, Single-center, Prospective Clinical Study.

Study ID: NCT04694183

Conditions

Stomach Neoplasms

Interventions

Study Description

Brief Summary: Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis rate.Studies have shown that patients with good pathological response after preoperative neoadjuvant therapy (such as tumor regression grade, TRG0 or 1) have a better prognosis.The purpose of this study is to treat patients with advanced gastric cancer who are difficult to perform R0 surgery with chemotherapy combined with immunotherapy. At the same time as the primary cancerous lesions are reduced, the distant metastatic lesions are effectively controlled in order to perform R0 surgery and to improve the survival rate of patients with advanced gastric cancer.

Detailed Description: The interventions include camrelizumab and chemotherapy selected based on the use of different metastatic sites as conversion therapy.